CBN and PHARMEXCIL sign MoU
Analysis based on 7 articles · First reported Aug 24, 2026 · Last updated Aug 25, 2026
The MoU is expected to streamline export procedures for compliant pharmaceutical exporters, potentially reducing dwell times and enhancing India's reputation as a reliable supplier. It may modestly benefit Indian pharmaceutical exporters by clarifying regulatory expectations and fostering a cooperative compliance environment, though the voluntary nature limits immediate financial impact.
On August 25, 2026, the Indonesia — National Narcotics Board (CBN), under India's Ministry of Finance, and the India — Pharmaceuticals Export Promotion Council of India (PHARMEXCIL), under the Ministry of Commerce and Industry, signed a Memorandum of Understanding (MoU) at CBN headquarters in Gwalior. The MoU aims to promote legitimate pharmaceutical exports while preventing the diversion of controlled substances. It establishes a voluntary code of conduct for the industry, facilitates information exchange, and plans joint workshops and awareness campaigns. The agreement is part of India's Ease of Doing Business roadmap and is the third such MoU by CBN with industry bodies, following agreements with the Indian Chemical Council (2022) and CHEMEXCIL (2025).
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard